REMS Abuses: Congressional Panel’s Focus Turns To Federal Trade Commission
Executive Summary
During bipartisan, but one-sided, hearing about US FDA’s limited authority to ensure generic drug makers can access restricted distribution reference products for bioequivalence testing, one lawmaker wants to know what FTC is doing about the issue.
You may also be interested in...
Congress’ Next Steps On REMS Abuses: Will Improving FDA-FTC Communication Help?
US FDA has seen little success in ending gaming of the patent process by brand name manufacturers. One problem: the agency’s referrals to FTC on anti-competitive cases appear go into a black box.
Generic Drug Roadblock: 74 Brands Subject To REMS, Other Restrictions
Report sponsored by Association for Accessible Medicines in US says drugs with restricted distribution programs had total sales of $22.7bn in 2016; seven drugs had sales topping $1bn.
Generic Drug Roadblock: 74 Brands Subject To REMS, Other Restrictions
Report sponsored by Association for Accessible Medicines in US says drugs with restricted distribution programs had total sales of $22.7bn in 2016; seven drugs had sales topping $1bn.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests:
